This is supported by observations in cancer immunotherapy, where high ERAP2 expression (the risk haplotype for BU) is a strong prognostic predictor of poor survival in patients receiving checkpoint inhibitor therapy to induce T-cell mediated antitumor immunity (53). Here, ERAP2 is linked to cancer.